6% hydroxyethyl starch 130/0.4

DRUG4 trials

Sponsors

Anders Perner, London Health Sciences Centre, Fresenius Kabi Japan, Asan Medical Center

Conditions

Coronary Artery Bypass SurgeryHemorrhageHypovolemiaPancreaticoduodenectomySeptic ShockSevere Sepsis

Phase 3

Scandinavian Starch for Severe Sepsis/Septic Shock Trial

CompletedNCT00962156

Anders PernerSeptic Shock, Severe Sepsis

Start: 2009-12-31End: 2012-03-31Updated: 2012-07-10

Trial of 6% HES130/0.4

CompletedNCT01010022

Fresenius Kabi JapanHemorrhage, Hypovolemia

Start: 2009-11-30End: 2010-11-30Updated: 2011-03-10

Comparison of Hemodynamic Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy

CompletedNCT01758172

Asan Medical CenterPancreaticoduodenectomy

Start: 2009-10-31End: 2012-01-31Updated: 2013-01-03

Unknown Phase

Starch or Saline After Cardiac Surgery

TerminatedNCT00964015

London Health Sciences CentreCoronary Artery Bypass Surgery

Start: 2009-08-31End: 2012-06-30Updated: 2019-08-15

Related Papers

How biomarkers reflect the prognosis and treatment of necrotising soft tissue infections and the effects of hyperbaric oxygen therapy: the protocol of the prospective cohort PROTREAT study conducted at a tertiary hospital in Copenhagen, Denmark

BMJ Open2017-10-014 citations

Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: a prospective study.

2015-04-24101 citations

Thromboelastography in patients with severe sepsis: a prospective cohort study.

2014-11-2152 citations

Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis.

2012-06-271031 citations

Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S--Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial.

2011-01-2745 citations